One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

The present invention relates to compound of formula (I): ##STR00001##
wherein
R is O—R.sub.3 or ##STR00002##
R.sub.1 and R.sub.2 are identical or different and are each independently H, (C.sub.1-C.sub.6)alkyl, —CO—(C.sub.1-C.sub.21)alkyl or —CO—(C.sub.11-C.sub.21)alkenyl group, provided that at least one of R.sub.1 or R.sub.2 is H or (C.sub.1-C.sub.6)alkyl,
R.sub.3 is a —CO—(C.sub.11-C.sub.21)alkyl or —CO—(C.sub.11-C.sub.21)alkenyl group,
or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof,
for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Provided herein is a composition comprising a mixture of ether lipid molecules of Formula (I) as defined herein. The composition is for invivo maintenance of ether lipids at levels and/or ratios associated with a non-disease state, or wherein the composition is for in vivo modification of ether lipids towards levels and/or ratios associated with a non-disease state. Also provided herein are methods of assessing subject for metabolic disease or dyslipidemia, comprising measuring relative abundance of one or more ether lipid side chains in a biological sample from a subject, methods of preventing or treating disorders such as metabolic disease or dyslipidemia, or methods of preventing conditions such as obesity and asthma, particularly in infants, involving administering a composition as defined herein.

Provided herein is a composition comprising a mixture of ether lipid molecules of Formula (I) as defined herein. The composition is for invivo maintenance of ether lipids at levels and/or ratios associated with a non-disease state, or wherein the composition is for in vivo modification of ether lipids towards levels and/or ratios associated with a non-disease state. Also provided herein are methods of assessing subject for metabolic disease or dyslipidemia, comprising measuring relative abundance of one or more ether lipid side chains in a biological sample from a subject, methods of preventing or treating disorders such as metabolic disease or dyslipidemia, or methods of preventing conditions such as obesity and asthma, particularly in infants, involving administering a composition as defined herein.

The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.

The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.